InMode Ltd. (INMD) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 20-F, InMode Ltd.'s filing signal continuing negative.

InMode Ltd. designs, develops, manufactures, and commercializes innovative, energy-based, minimally invasive surgical and medical treatment solutions primarily for the global aesthetics market. The company leverages proprietary radio frequency (RF) energy technologies, including RF Assisted Lipolysis (RFAL) and Deep Subdermal Fractional RF, to address face and body contouring, medical aesthetics, and women's wellness. Its product portfolio includes a range of platforms and handpieces, with a significant installed base of approximately 30,900 platforms as of December 31, 2025. InMode's strategy focuses on continuous innovation, expanding its product indications, and growing its global market presence, with international sales accounting for 46% of revenue in 2025.

Revenue is primarily generated from the sale of energy-based medical aesthetic products, which include platforms and non-consumable handpieces and hands-free applicators. A smaller portion of revenue comes from the sale of consumables and extended warranties.